BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 33,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 33,000 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00. Following the completion of the transaction, the chief executive officer directly owned 456,209 shares of the company’s stock, valued at approximately $44,621,802.29. The trade was a 6.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.

BioNTech Trading Up 2.9%

Shares of BNTX stock traded up $2.87 on Tuesday, reaching $100.87. 1,050,346 shares of the company’s stock were exchanged, compared to its average volume of 1,100,679. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $25.51 billion, a PE ratio of -12.88 and a beta of 1.29. The company’s fifty day simple moving average is $97.54 and its 200 day simple moving average is $94.82.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same period last year, the company earned ($1.60) EPS. The business’s revenue was down 59.5% compared to the same quarter last year. As a group, analysts forecast that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in BNTX. Larson Financial Group LLC raised its holdings in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in BioNTech in the second quarter worth about $39,000. Caitong International Asset Management Co. Ltd grew its holdings in BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after acquiring an additional 506 shares in the last quarter. Vestcor Inc bought a new position in BioNTech during the 4th quarter worth about $153,000. Finally, Rockefeller Capital Management L.P. increased its position in BioNTech by 328.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after purchasing an additional 1,423 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on BNTX. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Canaccord Genuity Group lowered their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Citigroup dropped their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Finally, Morgan Stanley decreased their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.